• Depot
  • Watchlist
  • Glocke
  • Handeln

    • Icecure Medical News

    1,20 $ +0,84% +0,01 $
    In : 1,1222 € | 26.04.24 22:00:00 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A1W1LG
    ISIN: IL0011224156
    US-Symbol: ICCM
    Typ: Aktie

    Icecure Medical News

    15.04.24 - PR Newswire
    IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer
    IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA ...
    03.04.24 - PR Newswire
    IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance
    IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and ...
    02.04.24 - PR Newswire
    IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes
    IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes PR Newswire
    27.03.24 - PR Newswire
    IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024
    IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 PR Newswire
    19.03.24 - PR Newswire
    IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
    IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to ...
    12.03.24 - PR Newswire
    IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes
    IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes PR Newswire
    07.03.24 - PR Newswire
    IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference
    IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference PR Newswire
    04.03.24 - PR Newswire
    IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024
    IceCure's ProSense® a Promising Alternative Treatment for Extra-​Pelvis Endometriosis: Independent Study Presented at ECR 2024 PR Newswire
    27.02.24 - PR Newswire
    Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop
    Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop PR Newswire
    26.02.24 - PR Newswire
    Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer
    Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-​Stage Breast Cancer PR Newswire
    15.02.24 - PR Newswire
    IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan
    IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan PR Newswire
    30.01.24 - PR Newswire
    U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer
    U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-​Stage Breast Cancer PR Newswire
    29.01.24 - PR Newswire
    IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class
    IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class PR ...
    16.01.24 - PR Newswire
    IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation
    IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation PR Newswire
    10.01.24 - PR Newswire
    IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results
    IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results PR Newswire
    03.01.24 - PR Newswire
    New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response
    New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response PR Newswire
    13.12.23 - PR Newswire
    Study Using IceCure's ProSense® Finds: "Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients"
    Study Using IceCure's ProSense® Finds: "Cryoablation Allows the Ultimate De-​escalation of Surgical Therapy for Select Breast Cancer Patients" PR Newswire
    29.11.23 - PR Newswire
    IceCure's ProSense® Deepens Regulatory Approval in India
    IceCure's ProSense® Deepens Regulatory Approval in India PR Newswire
    28.11.23 - PR Newswire
    IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate
    IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-​Free Survival Rate and 100% Secondary Local Control Rate PR Newswire
    15.11.23 - PR Newswire
    IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights
    IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights PR Newswire

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »